New PAH drug IKT-001 enters final testing phase
NCT ID NCT07365332
First seen Feb 02, 2026 · Last updated May 15, 2026 · Updated 13 times
Summary
This study tests an experimental drug called IKT-001 for people with pulmonary arterial hypertension (PAH), a condition where high blood pressure in the lungs makes it hard to breathe and move. The trial will compare IKT-001 to a placebo in 486 adults to see if it improves blood flow and walking distance. Participants must be 18-75 years old with certain types of PAH.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PULMONARY ARTERIAL HYPERTENSION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Norton Healthcare
RECRUITINGLouisville, Kentucky, 40202, United States
-
Tufts Medical Center
RECRUITINGBoston, Massachusetts, 02111, United States
Conditions
Explore the condition pages connected to this study.